Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Presentation (November 2023)
52 slides from Perspective Therapeutics's investor presentation, Nov 28, 2023
Slide 1: Corporate Presentation
PERSPECTIVE THERAPEUTICS Corporate Presentation NYSE: CATX
Slide 2: Legal Disclaimers
Legal Disclaimers ‘nis presentation contains rorwardsooking statements within the meaning ofthe Unted States Private Securities Legation Reform Act of 2985. Statementsin this presentation that are nat “statements of historical fect are forvaralooking statements. Words suchas “may.” “wl,” “should, "“
Slide 3: Investment Highlights
Investment Highlights + Radiopharmaceutical company focused on pan-cancer opportunities with a 2"? generation a-emitter platform + Two clinical-stage programs in addition to a robust pre-clinical pipeline + VMT- NET - First in human trial ongoing for neuroendocrine tumors + VMT-01 - Targeting the me
Slide 4: Platform Expansion Engine, Two Lead Programs in Clinic and Broad Proprietary Pipeline
Platform Expansion Engine, Two Lead Programs in Clinic and Broad Proprietary Pipeline Human Firstin Clinical | Human. Indication Discovery | Imaging | Therapy | Phase 1/2| Phase3 Neuroendocrine cancer VMT-eNET Pheochromocytomas, paragangliomas ‘Small cell lung cancer VMT-OL Melanoma (MC1R) VMT-02(PE
Slide 5: Our Pipeline With Multiple Near-Term Data Readouts
Our Pipeline With Multiple Near-Term Data Readouts Pipeline ae ae H | ; | : Program Ineaton eatin oes | 3025e THERAPEUTICS
Slide 6: Radiopharmaceuticals are a Pillar of Oncology Treatment with Pan-Cancer Opportunities
Radiopharmaceuticals are a Pillar of Oncology Treatment with Pan-Cancer Opportunities Molecularly Targeted Radiation Optimized Patient Selection Monotherapy Activityand mbination Synergies Outpatient Friendly Unique Business, Opportunity Radioligands can precisely deliver radiation directly to cance
Slide 7: Targeted a-Particle Radiotherapy
Targeted a-Particle Radiotherapy A New Class of Oncology Therapeutics
Slide 8: Perspective's Radiopharmaceutical Optimization Process
Perspective’s Radiopharmaceutical Optimization Process Targeting Peptide Engineered for cancer: cific receptors to Isotope °3Pl for SPECT imaging or 212ph for alpha particle therapy ensure highly directed uptake Linker Chelator Selected to assist peptide binding Perspective’s proprietary platform an
Slide 9: Lead-212: The Optimal Therapeutic Isotope
Lead-212 (71Pb): The Optimal Therapeutic Isotope Greater Therapeutic Energy Expected to Improve Outcome with Better Safety lodine Lutetium Actinium Lead (5) (@77Lu) | (22Ac) (222Pb) Implication Emission Profile Beta Beta Alpha Alpha Potent Half Life 8 days 6.7 days 410 days 0.46 days Rapid Clearance
Slide 10: Chelator Optimized for 212/203Pb
Chelator Optimized for 242/2°3Pb i ‘ou yon cele 7 TCMC wo Commercially Available fe} HON. HON. oO _— “e a g Improves: radiolabeling renal clearance receptor binding internalization (oP JD. —_ Proprietary Perspective IP Generic chelators leave formal charge at chelator/radiometal coupling (positive o
Slide 11: Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer
Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer Identical Distribution of 2Pb and 2#2Pb for Imaging and Treatment, Respectively 24 hours: e it) Tyo = 52h Dosimetry en 203Ph Linker Targeting Cancer Cell imaging surrogate Ligand x. Patient Selection Therapeutic (Treat it)
Slide 12: Neuroendocrine Tumors: VMT-a-NET
Neuroendocrine Tumors: VMT-a-NET Targeting the somatostatin receptor to treat rare neuroendocrine- type cancers
Slide 13: VMT-a-Net Currently in Phase 1/2a Studies
VMT-a-Net Currently in Phase1/2a Studies Key Facts Targeting somatostatin receptor type 2 (SSTR2) for the imagingand treatment of neuroendocrine tumors Initiated firstin-human imaging (2021) & therapy (2022) under compassionate use @ Fast Track Designation received October 2022 Open IND for Therapeu
Slide 14: SSTR2 is an Attractive Target for Identifying and Treating Tumors
SSTR2 is an Attractive Target for Identifying and Treating Tumors Expressed Across Several Tumor Types Neuroendocrine tumors (NETs) SSTR2is expressed widely in various tumors + Meningioma + Neuroendocrine cells are specialized cells that secrete hormones and other bioactive + Pituitary adenomas + Na
Slide 15: VMT-a-NET is Developed to Address the Unmet Need in NETs
VMT-a@-NET is Developed to Address the Unmet Need in NETs Current Standard of Care limited to subset of NETs patients Significant unmet need: * ~12Knewdiagnoses annually in the US? aot annie + Treatment depends on the type of tumor. Some approaches may include surgery. radiation, and chemotherapy *
Slide 16: Imaging Shows Superiority of Perspective's Platform Technology vs Generic Compounds
Imaging Shows Superiority of Perspective’s Platform Technology vs Generic Compounds Decreased Off-Target Toxicity, Increased Tumor Uptake and Retention in Preclinical Studies Key Take ‘old improved tumor uptake ney retention decreased A PERSPECTIVE THERAPEUTICS
Slide 17: VMT-a-NET Shows Improvements vs Standard of Care in Preclinical Models
VMT-a-NET Shows Improvements vs Standard of Care in Preclinical Models [?#2Pb] VMT-o-NET (120 pCi) fof f Smee [22Pb] VMT-o-NET (4X30 Ci) 0 ‘Fon — 13 ite je een {) Orug Administered PERSPECTIVE, THERAPEUTICS v
Slide 18: 203Pb SPECT Imaging Reveals Favorable VMT-a-NET Properties
203Pb SPECT Imaging Reveals Favorable VMT-a-NET Properties Rapid Maas fargeting and Renal High Tumor Retention sarance 1.5hrs SPECT/CT y J 22 hrs - ? e? ‘SPECT/CT =e - Ps 4 + Tumors visible within 4 hour. a high intensity above background oo + Unbound drug in bladder within 1 hour, low renal retenti
Slide 19: Significant Response After Single Dose, Almost Complete Response After 3 Doses
Significant Response After Single Dose, Almost Complete Response After 3 Doses Patient 1: Metastatic NET Pancreas with Adrenal Crisis Tumor Before Treatment Tumor After 1 Dose Tumor After 3 Doses S.ACTH - 96 pg/ml PERSPECTIVE THERAPEUTICS %
Slide 20: Clinical Investigation of [212Pb]VMT-a-NET in Metastatic SSTR2 Positive Patients
Clinical Investigation of [?17Pb]VMT-a-NET in Metastatic SSTR2 Positive Patients Current Status + Patients with prior lines of therapy, late-stage, anatomically different NETs (mean age: 48 years; 4 females) + 40 patients administered (2!2Pb]VMT-a-NET Tease + 7/10 patients continuing on therapy Dire
Slide 21: High Partial Response Rate at Starting Dose in Patients with SSTR+, Late-Stage NETs
High Partial Response Rate at Starting Dose in Patients with SSTR+, Late-Stage NETs Interim Results as of September 28, 2023, for Clinical Investigation Program in India Saag Ox Crd = Ak Ok p faz Ox Ox } Se Va | _ ae © Periatnessnce PT a > oe A ssteDuene car oo @ Pree Dose =——, Paton 10 4 02 ERED #1
Slide 22: Phase 1/2a [212Pb]VMT-a-NET Trial — Commenced November 2023
Phase 1/2a [?!?7Pb]VMT-a-NET mTPI-21[NCT05636618] — Commenced November 2023 Primary Objective Population Escalationn~ 10:3 Expansion n = 20-100 Escalation phase To determine the MTO/MFD of =PLIVMTEGNET (RP20) Imag FDA approved SSTR2 PET/CT TherapeuticDose Unresectable or metastatic SSTR2-positve neu
Slide 23: Melanoma Program: VMT01/02
Melanoma Program: VMT01/02 Using the melanocortin receptor MC1R to target melanoma for imaging and therapy
Slide 24: VMT01 Currently In Phase 1/2a Studies
VMTO1 Currently In Phase1/2a Studies Preclinical combination data (published) resulted in $2m NIH SBIR Grant Results from completed Phase 1 imaging study presented in Q2 2023 Study was conducted at the Mayo Clinic Rochester Open IND for Therapeutic Trial with first patient treated Pending Orphan Dru
Slide 25: Metastatic Melanoma
Metastatic Melanoma Brain Lymph nodes Lungs skin (Primary) Ever [2#2PD]VMT-O1 target indication: MCIR-positive melanoma + Market opportunity of $8 billion in 2028" + Significant unmet need in the US: + ~100K new diagnoses annually? + 8,000 people die from melanoma every year? Treatment depends on th
Slide 26: [203Pb]VMT-01 Images Shows Clear Uptake in MC1R-positive Melanoma
P?Pb]VMT-01 Images Shows Clear Uptake in MC1R-positive Melanoma | Melanoma | Human Melanoma High intensity in implanted tumor above background _High intensity in esophageal tumor above background @ Preclinical microSPECT Whole body planar SPECT/CT E PERSPECTIVE THERAPEUTICS
Slide 27: VMT01/02 Demonstrated Complete Responses in Multiple Animal Tumor Models
VMT01/02 Demonstrated Complete Responses in Multiple Animal Tumor Models ome Single dose of VMTO1 significantly arrested zi ue melanoma tumor growth and extended survival? + High response rates in multiple tested 400: Immunodeficient human ‘melanoma xenoggaft model ~ models B so BRAF positive 2 + 43
Slide 28: Phase 1/2a [212Pb]VMT01-T101 Trial — Commenced August 2023
Phase 1/2a [?!2Pb]VMTO01-T101 mTPI! [NCT05655312] — Commenced August 2023 Primary Objective To determine the MTO/MFO of =PLIVMTOLT101 (RP20) ines (%PH]VMTOL SPEC/CT or [€GalvMTO2 PET/CT Therapeutic Dose Unresectable or metastatic MCAR-positive Melanoma Estimated Timeto Primary Completion, ‘= 15 mCi
Slide 29: Manufacturing, Production and Logistics of 212Pb-labeled Therapeutics
Manufacturing, Production and Logistics of 212Pb-labeled Therapeutics The Path to Commercial Supply
Slide 30: As a Medical Isotope, 212Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics
As a Medical Isotope, 7"7Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics The supply chain is lower-risk and more robust than other therapeutic isotopes Isotope Source Isotope Purification Product Manufacturing + Naturally occurring in mining waste + ‘Parent isotope Thorium-2
Slide 31: 212Pb Supply via Reusable Desktop Isotope Generator
212Pb Supply via Reusable Desktop Isotope Generator VMT-a-GEN + Extensive feedstock from nuclear and mining waste material + Long-term supply contract secured with US DOE * On demand daily doses + Auto-regenerates overnight + ~1 week shelf life mall, Elegant 712Pb Isotope Generator + Integrated lead
Slide 32: Scalable Manufacturing and Distribution Logistics
Scalable Manufacturing and Distribution Logistics Perspective’s plan to flexibly scale manufacturing to commercial levels (100,000+ doses per year) isottes mon oun andshippea l => ore > Process tocoMO > 7 ra Ha Scaled Large hes Dispensing Delivery Conncal| tine GO, coment a aaa COMI InoEe GEERT =a +
Slide 33: Infrastructure and Distribution Networks for Radiopharmaceuticals are Mature
Infrastructure and Distribution Networks for Radiopharmaceuticals are Mature Existing radiopharmacies have established logistics for distributed supply Map of US Radiopharmacies* + There were 40+ million diagnostic nuclear medicine procedures performed in the US in in 2022 + Multiple networks exist
Slide 34: Regional Manufacturing Allows Commercialization of 212Pb-labeled Finished Products
Regional Manufacturing Allows Commercialization of ?!?Pb-labeled Finished Products Limited number of sites allows for “network effect” to ensure robust supply chain Radius 400m Location) population Coralville, 1A 51 million New York, NY 75 million Los Angeles, CA. 46 million Austin, 1X 32 million At
Slide 35: Corporate Overview
Corporate Overview
Slide 36: Management Team
Management Team Deep Radiotherapy and Development Experience @ ® @ Thijs Spoor Jonathan Hunt Markus Puhlmann MD MBA Chief Executive Chief Financial Chief Mediicat Officer Officer Officer 20+ years of expertise in biotechnology companies; public and 20+ years of expertise 20+ years of oncology infina
Slide 37: Strong Intellectual Property Portfolio
Strong Intellectual Property Portfolio Fully Licensed University/Perspective owned IP [ES IP Portfolio covers all aspects of Bprevsionalpatents NF radiopharmaceutical value chain + Composition of Matter and Use VMT-o-NET, chelator, Isotope generator and novel pan-cancer product (U.S.. E.U., Australi
Slide 38: Appendix
Appendix
Slide 39: a-Particles Have Superior Tumor Killing Properties vs. b-Particles
a-Particles Have Superior Tumor Killing Properties vs. 6-Particles More Powerful Effects Than Approved B. Therapy Higher atomic mass Lethal double-stranded DNA breaks DNA repair mechanisms overwhelmed Precision Delivery Provides Targeted Cell Destruction Deposit energy over 3-5 cell diameters vs. be
Slide 40: Lead (Pb): The Ideal Theranostic Isotope
Lead (Pb): The Ideal Theranostic Isotope Ideal Theranostic Requirements Solutions: 2047212 ive Chelator Ideal agreement between imaging and therapeutic compounds @ Readilyavailable isotope @ Ideal chelator @ Rapid clearance from blood © High tumor retention @24 hours Shortt gives rapid effect while
Slide 41: Peptides are Ideal Ligands for Radiopharmaceutical Therapy
Peptides are Ideal Ligands for Radiopharmaceutical Therapy Monoclonal antibodies Kinetics mAb Kinetics Tumor penetration tow Clearance: Hepatobiliary (iver) Bleed cerencer ene ved Biological ¥ Life: ong 8 Target affinity: High & ator Sater & || tortoxeiy tumor accumulation: extended Stability Questi
Slide 42: Isotope: Decay chain — Biological implications
Isotope: Decay chain — Biological implications Alpha-particle emission imparts sufficient 225, i "Ac Decay Series fo) “recoil” energy to break chemical bonds. Bae ei OH soa | fe) ae em eb Joa] ar 6; OH i 6e PERSPECTIVE THERAPEUTICS 2
Slide 43: Isotope: Decay chain — Product implications
Isotope: Decay chain — Product implications Post final radiolabeling and purification, alpha and beta emitting daughters of 25Ac build up fast A Decay and Daughter ingrowth MAC225 wFr-221 wALZIT mBL213 "T1209 mPO-213 Dose Vial care 6000 Radiometals: | 4x more unlabeled daughter activity in about 4 h
Slide 44: Isotope: Decay chain and chelator selection
Isotope: Decay chain and chelator selection 212Pb Decay Series ou Parent Material —— ane | “R2 | Ral??Pb Generator ay te] Bala ay y ay 26Po 2B 208Pb 01s 61min| B +| stable ay B ay ya 22h all Wh 3 min [22Pb]Psct *PSC= Lead (Pb)-Specific Chelator PERSPECTIVE THERAPEUTICS “
Slide 45: Clinical Trial Principal Investigators
Clinical Trial Principal Investigators Renowned Experts in Radiotherapy Development Geoffrey B Johnson MD, PhD Chair, Division of Nuclear Chair, PET/MR R&D. Associate Professor Departments of Radiology and. Immunology ‘Mayo Clinic - Rochester, MN Vikas Prasad MD = Wishing Universi in Sts Professor o
Slide 46: Appendix: VMT-a-NET
Appendix: VMT-a-NET Additional Clinical Investigation Data
Slide 47: Significant Tumor Response After Two Doses
Significant Tumor Response After Two Doses Patient 3: Metastatic NET Pancreas with Liver Metastases Liver Metastases beforetreatment MIP image MIP image Before After 2"4 Treatment Treatment Dr Dharmender Malik i, Gurugram, India. Presentedat PERSPECTIVE tren THERAPEUTICS
Slide 48: Reduction in Size of Necrotic Masses After Doses
Reduction in Size of Necrotic Masses After 2 Doses Patient 5: NET Pancreas Tumor Before Treatment Tumor After Treatment PERSPECTIVE THERAPEUTICS = tis Memorial research 8 of Septembs India. Presentedat
Slide 49: Favorable Safety and Tolerability Profile
Favorable Safety and Tolerability Profile Four Months Post-Treatment (5 Patients) Hemoglobin Levels Total Leukocyte Count HeneawoL Tine prt) “Tine oft) Time eit) 2 Time ere) ‘Dr Dharmender Malik, Fortis Memorial research institute (FMRI, Gurugram, India, Presentedat PERSPECTIVE [EANM 2023-Intenm Res
Slide 50: Serious Adverse Event in Patient
Serious Adverse Event in Patient 6 Acute Cardiac Event Unrelated to Study Drug Patient Profile + 25 yearmale + Metastatic NET-pancreas + Longstanding disease (>6 years duration) + Heavily pre-treated with Inj. Sandostatin and 4 cycles of 277Lu- DOTATATE along with CAPTEM regimen Received 1 dose of [
Slide 51: Serious Adverse Event in Patient
Serious Adverse Event in Patient 2 Myelodysplastic syndrome (MDS) Unrelated to Study Drug Patient Profile + 79 year-male + Metastatic Medullary Carcinoma thyroid + Disease progression of TKI's + Received total 3 doses of (22Pb]VMT-o-NET therapy at an a interval of 8 weeks (Cumulative ® dose 9.6 mCi)
Slide 52: Slide 52
Perspective Therapeutics — Investor Presentation (November 2023) on 6ix